MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
MicroRNAs comprise a broad class of small non-coding RNAs that control expression of complementary target messenger RNAs. Dysregulation of microRNAs by several mechanisms has been described in various disease states including cardiac disease. Whereas previous studies of cardiac disease have focused on microRNAs that are primarily expressed in cardiomyocytes, the role of microRNAs expressed in other cell types of the heart is unclear. Here we show that microRNA-21 (miR-21, also known as Mirn21) regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK-MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy. In vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis and attenuates cardiac dysfunction. These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts. Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic manipulation through long non-coding RNAs, miRNA modulators, and other oligonucleotides has yielded promising outcomes in experimental settings.162–165”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [162]
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Self-citationA microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1569 · Cited by 1,138
Cited by
Items 101–200 of 1,006
MicroRNAs and cardiac pathology
Latronico, M. V. G., & Condorelli, G. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.56 · Cited by 324
Inhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model
Hinkel, R., Penzkofer, D., Zühlke, S., Fischer, A., Husada, W., Xu, Q.-F., Baloch, E., van Rooij, E., Zeiher, A. M., Kupatt, C., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001904 · Cited by 317
Sayed, D., He, M., Hong, C., Gao, S., Rane, S., Yang, Z., & Abdellatif, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.109207 · Cited by 315
Pan, Z., Sun, X., Shan, H., Wang, N., Wang, J., Ren, J., Feng, S., Xie, L., Lu, C., Yuan, Y., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.094524 · Cited by 312
“Le miARN-21 stimule les protéines kinases activées par des mitogènes et régulées par les signaux extracellulaires en inhibant le gène SPRY1 (pour sprouty homolog 1) et module par là même la survie des fibroblastes et la sécrétion de facteur de croissance.(16) Il a également été établi que le miARN-21 contrôle l’expres…”
MethodEgea, J., Fabregat, I., Frapart, Y. M., Ghezzi, P., Görlach, A., Kietzmann, T., Kubaichuk, K., Knaus, U. G., Lopez, M. G., Olaso-Gonzalez, G., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.05.007 · Cited by 310
MicroRNAs in idiopathic pulmonary fibrosis
Pandit, K. V., Milosevic, J., & Kaminski, N. (2011) · Translational Research · doi:10.1016/j.trsl.2011.01.012 · Cited by 311
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells
Wang, P., Zou, F., Zhang, X., Li, H., Dulak, A., Tomko, R. J., Lazo, J. S., Wang, Z., Zhang, L., & Yu, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1996 · Cited by 308
MicroRNAs in Heart Failure: From Biomarker to Target for Therapy
Vegter, E. L., van der Meer, P., de Windt, L. J., Pinto, Y. M., & Voors, A. A. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.495 · Cited by 303
de Boer, R. A., De Keulenaer, G., Bauersachs, J., Brutsaert, D., Cleland, J. G., Diez, J., Du, X.-J., Ford, P., Heinzel, F. R., Lipson, K. E., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1406 · Cited by 304
Self-citationThe fibrosis-cell death axis in heart failure
Piek, A., de Boer, R. A., & Silljé, H. H. W. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9536-9 · Cited by 301
MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment
Quiat, D., & Olson, E. N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62876 · Cited by 300
“Pharmacological antagonism of miR-21 with antagomir exhibits antihy-pertrophic and antifibrotic effects, resulting in functional improvement following hypertrophic stress (80).”
Qiao, L., Hu, S., Liu, S., Zhang, H., Ma, H., Huang, K., Li, Z., Su, T., Vandergriff, A., Tang, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123135 · Cited by 303
“reported that miR-21 expression is highly upregulated by cardiac stress, leading to activation of ERK/MAP kinase signaling through inhibition of Spry1, which in turn promoted cardiac fibrosis and heart dysfunction (39).”
BackgroundMicroRNA-21 Blocks Abdominal Aortic Aneurysm Development and Nicotine-Augmented Expansion
Maegdefessel, L., Azuma, J., Toh, R., Deng, A., Merk, D. R., Raiesdana, A., Leeper, N. J., Raaz, U., Schoelmerich, A. M., McConnell, M. V., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003441 · Cited by 301
TGF-β 1/Smads and miR-21 in Renal Fibrosis and Inflammation
Loboda, A., Sobczak, M., Jozkowicz, A., & Dulak, J. (2016) · Mediators of Inflammation · doi:10.1155/2016/8319283 · Cited by 297
“Likewise in cardiac injury [72], miR-21 was also found to stimulate ERK/MAPK signaling in the kidney.”
BackgroundKumarswamy, R., Volkmann, I., Jazbutyte, V., Dangwal, S., Park, D.-H., & Thum, T. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.234286 · Cited by 293
Self-citationCirculating MicroRNAs as Biomarkers and Potential Paracrine Mediators of Cardiovascular Disease
Gupta, S. K., Bang, C., & Thum, T. (2010) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.110.958363 · Cited by 292
“(3) Exosomes also may bind to surface receptors on target cells following internalization by the target cells through endocytosis.”
BackgroundSelf-citationDiabetes Complications: The MicroRNA Perspective
Kantharidis, P., Wang, B., Carew, R. M., & Lan, H. Y. (2011) · Diabetes · doi:10.2337/db11-0082 · Cited by 289
“Atherosclerosis miR-16 COX-2 (39) indirect† miR-503? CCNE1, cdc25A (40) Heart miR-21 SPRY1 (50,51) miR-29 Collagens (17) miR-30? CTGF (48) indirect† miR-1/133 ERG, RhoA, Cdc42, WHSC2, HCN1, and HCN4 (44–47)”
BackgroundMarin, T. M., Keith, K., Davies, B., Conner, D. A., Guha, P., Kalaitzidis, D., Wu, X., Lauriol, J., Wang, B., Bauer, M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44972 · Cited by 282
Shah, A. M., & Mann, D. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60894-5 · Cited by 284
Targeting TGF-β signaling for the treatment of fibrosis
Györfi, A. H., Matei, A.-E., & Distler, J. H. W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.016 · Cited by 274
Nielsen, B. S., Jørgensen, S., Fog, J. U., Søkilde, R., Christensen, I. J., Hansen, U., Brünner, N., Baker, A., Møller, S., & Nielsen, H. J. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9355-7 · Cited by 272
“In various settings, miR-21 has been reported to affect expression of the transcription factor NF1-B in PMAstimulated HL60 cells [16], Spry1 in cardiac fibroblasts [19], the tumor suppressor PTEN in hepatocytes and cardiac fibroblasts [22, 23], and the tumor suppressor PDCD4 in a variety of cell lines [17, 51].”
BackgroundInfluentialAging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling
Horn, M. A., & Trafford, A. W. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.11.005 · Cited by 275
Karakikes, I., Chaanine, A. H., Kang, S., Mukete, B. N., Jeong, D., Zhang, S., Hajjar, R. J., & Lebeche, D. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000078 · Cited by 266
Kalla, R., Ventham, N. T., Kennedy, N. A., Quintana, J. F., Nimmo, E. R., Buck, A. H., & Satsangi, J. (2015) · Gut · doi:10.1136/gutjnl-2014-307891 · Cited by 267
MicroRNAs: Roles in Regulating Neuroinflammation
Gaudet, A. D., Fonken, L. K., Watkins, L. R., Nelson, R. J., & Popovich, P. G. (2018) · The Neuroscientist · doi:10.1177/1073858417721150 · Cited by 236
Micro RNA‐24 regulates cardiac fibrosis after myocardial infarction
Wang, J., Huang, W., Xu, R., Nie, Y., Cao, X., Meng, J., Xu, X., Hu, S., & Zheng, Z. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01523.x · Cited by 266
“For example, miR-21 and miR-29 have been found to have important roles in the growth and apoptosis of cardiac cells [32, 33], and in cardiac fibrosis remodelling [8, 9].”
BackgroundCell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects
Zhang, X., Li, Y., Chen, Y. E., Chen, J., & Ma, P. X. (2016) · Nature Communications · doi:10.1038/ncomms10376 · Cited by 268
Long, J., Wang, Y., Wang, W., Chang, B. H. J., & Danesh, F. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.194969 · Cited by 266
MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction
Meder, B., Keller, A., Vogel, B., Haas, J., Sedaghat-Hamedani, F., Kayvanpour, E., Just, S., Borries, A., Rudloff, J., Leidinger, P., et al. (2011) · Basic Research in Cardiology · doi:10.1007/s00395-010-0123-2 · Cited by 265
“also is upregulated in the myocardium during the early phase of infarction [11, 36].”
BackgroundSelf-citationSantiago, J., Dangerfield, A. L., Rattan, S. G., Bathe, K. L., Cunnington, R. H., Raizman, J. E., Bedosky, K. M., Freed, D. H., Kardami, E., & Dixon, I. M. C. (2010) · Developmental Dynamics · doi:10.1002/dvdy.22280 · Cited by 269
Varasteh, Z., Mohanta, S., Robu, S., Braeuer, M., Li, Y., Omidvari, N., Topping, G., Sun, T., Nekolla, S. G., Richter, A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.226993 · Cited by 256
MicroRNAs and the regulation of fibrosis
Jiang, X., Tsitsiou, E., Herrick, S. E., & Lindsay, M. A. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07632.x · Cited by 258
“In turn, this promoted fibroblast survival and fibroblast growth factor (FGF) secretion leading to fibroblast proliferation and ECM/collagen deposition in vitro [23].”
BackgroundInfluentialCirculating Biomarkers of Myocardial Fibrosis
López, B., González, A., Ravassa, S., Beaumont, J., Moreno, M. U., San José, G., Querejeta, R., & Díez, J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.04.026 · Cited by 258
“It has been shown experimentally that microRNA-21 regulates the activity of cardiac fibroblasts and participates in the development of myocardial fibrosis (25).”
BackgroundParticipation of miR-200 in Pulmonary Fibrosis
Yang, S., Banerjee, S., de Freitas, A., Sanders, Y. Y., Ding, Q., Matalon, S., Thannickal, V. J., Abraham, E., & Liu, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.10.005 · Cited by 259
Role of miR-21 in the pathogenesis of atrial fibrosis
Adam, O., Löhfelm, B., Thum, T., Gupta, S. K., Puhl, S.-L., Schäfers, H.-J., Böhm, M., & Laufs, U. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-012-0278-0 · Cited by 255
“Recent evidence shows that the microRNA-21 (miR-21) and its downstream target Sprouty1 (Spry1), a potent inhibitor of the Ras/MEK/ERK pathway [13, 23, 44, 64] play a role in the pathogenesis of ventricular fibrosis in patients with congestive heart failure [60].”
BackgroundSelf-citationMicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells
Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., Lambert, V., Gonzalez, M.-L. A., Colige, A., Rakic, J.-M., Noël, A., Martial, J. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016979 · Cited by 254
“The regulator of MAPK activation Sprouty1, whose antiangiogenic potential has already been demonstrated [24], is targeted by miR-21 in cardiac fibroblasts [25].”
BackgroundMicroRNAs as Therapeutic Targets and Biomarkers of Cardiovascular Disease
Olson, E. N. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009008 · Cited by 255
Lino Cardenas, C. L., Henaoui, I. S., Courcot, E., Roderburg, C., Cauffiez, C., Aubert, S., Copin, M.-C., Wallaert, B., Glowacki, F., Dewaeles, E., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003291 · Cited by 251
“MiRNA expression profiling using high-throughput genomic approaches has provided important new insights into the pathogenesis, classification, diagnosis, stratification, and prognosis of many human diseases including tissue fibrosis [15,35,36].”
BackgroundMicroRNA29: A Mechanistic Contributor and Potential Biomarker in Atrial Fibrillation
Dawson, K., Wakili, R., Ördög, B., Clauss, S., Chen, Y., Iwasaki, Y., Voigt, N., Qi, X. Y., Sinner, M. F., Dobrev, D., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.001207 · Cited by 252
The involvement of microRNAs in neurodegenerative diseases
Maciotta, S., Meregalli, M., & Torrente, Y. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00265 · Cited by 245
Non-coding RNAs in Cardiac Remodeling and Heart Failure
Kumarswamy, R., & Thum, T. (2013) · Circulation Research · doi:10.1161/circresaha.113.300226 · Cited by 249
Self-citationMiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis
Nagpal, V., Rai, R., Place, A. T., Murphy, S. B., Verma, S. K., Ghosh, A. K., & Vaughan, D. E. (2016) · Circulation · doi:10.1161/circulationaha.115.018174 · Cited by 244
“mediating cardioprotective effects and the progression of cardiovascular disease.(8,25,27,30,31,41,42) There is a growing consensus that”
BackgroundSchuler, G., Adams, V., & Goto, Y. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht111 · Cited by 244
MicroRNAs in Vascular and Metabolic Disease
Zampetaki, A., & Mayr, M. (2012) · Circulation Research · doi:10.1161/circresaha.111.247445 · Cited by 244
Identification of a microRNA signature in renal fibrosis: role of miR-21
Zarjou, A., Yang, S., Abraham, E., Agarwal, A., & Liu, G. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00273.2011 · Cited by 241
“The mode of action for miR-21 in renal fibrosis could be distinct from that in the heart or lungs because the cell populations that harbor the enhanced miR-21 expression are different and the pathogenesis of kidney injury is unique based on the diverse nature of cells in the kidney (26, 39, 47).”
InfluentialOlivieri, F., Antonicelli, R., Lorenzi, M., D'Alessandra, Y., Lazzarini, R., Santini, G., Spazzafumo, L., Lisa, R., La Sala, L., Galeazzi, R., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.01.075 · Cited by 242
“It is known that miR-21 is highly expressed in cardiac fibroblasts and modulates fibrosis [34] [35] [36].”
BackgroundMacrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure
Heymans, S., Corsten, M. F., Verhesen, W., Carai, P., van Leeuwen, R. E. W., Custers, K., Peters, T., Hazebroek, M., Stöger, L., Wijnands, E., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.001357 · Cited by 238
Self-citationSchelbert, E. B., Piehler, K. M., Zareba, K. M., Moon, J. C., Ugander, M., Messroghli, D. R., Valeti, U. S., Chang, C. H., Shroff, S. G., Diez, J., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002613 · Cited by 237
“Dyslipidemia, n (%) 234 (40) 214 (37) 0.”
Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling
Sassi, Y., Avramopoulos, P., Ramanujam, D., Grüter, L., Werfel, S., Giosele, S., Brunner, A.-D., Esfandyari, D., Papadopoulou, A. S., De Strooper, B., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01737-4 · Cited by 234
Self-citationMicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis
Murugaiyan, G., da Cunha, A. P., Ajay, A. K., Joller, N., Garo, L. P., Kumaradevan, S., Yosef, N., Vaidya, V. S., & Weiner, H. L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci74347 · Cited by 239
Tillmanns, J., Hoffmann, D., Habbaba, Y., Schmitto, J. D., Sedding, D., Fraccarollo, D., Galuppo, P., & Bauersachs, J. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.08.016 · Cited by 237
“Because of their central role in cardiac remodeling, fibroblasts are under investigation as therapeutic targets in ischemic cardiomyopathy [7].”
BackgroundSelf-citationPerdiguero, E., Sousa-Victor, P., Ruiz-Bonilla, V., Jardí, M., Caelles, C., Serrano, A. L., & Muñoz-Cánoves, P. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201104053 · Cited by 236
“…of the timing or specification of the inflammatory response can lead to aberrant regeneration and pathological conditions, for example, the persistence of macrophages in dystrophic muscle is thought to contribute to disease progression (Tidball, 2005; Vidal et al., 2008; Villalta et al., 2009).”
MicroRNA 21 Blocks Apoptosis in Mouse Periovulatory Granulosa Cells1
Carletti, M. Z., Fiedler, S. D., & Christenson, L. K. (2010) · Biology of Reproduction · doi:10.1095/biolreprod.109.081448 · Cited by 234
miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development
Maegdefessel, L., Spin, J. M., Raaz, U., Eken, S. M., Toh, R., Azuma, J., Adam, M., Nagakami, F., Heymann, H. M., Chernugobova, E., et al. (2014) · Nature Communications · doi:10.1038/ncomms6214 · Cited by 235
“Signature miRNA (dys)regulation patterns exist for several cardiovascular disorders, including cardiac hypertrophy 25 , myocardial infarction 26 , atherosclerosis 27 , and peripheral artery disease 28 .”
Mechanical control of cardiac myofibroblasts
van Putten, S., Shafieyan, Y., & Hinz, B. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.11.025 · Cited by 234
Wu, X., Simpson, J., Hong, J. H., Kim, K.-H., Thavarajah, N. K., Backx, P. H., Neel, B. G., & Araki, T. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44929 · Cited by 234
Asl, E. R., Amini, M., Najafi, S., Mansoori, B., Mokhtarzadeh, A., Mohammadi, A., Lotfinejad, P., Bagheri, M., Shirjang, S., Lotfi, Z., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119499 · Cited by 231
MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice
Horie, T., Nishino, T., Baba, O., Kuwabara, Y., Nakao, T., Nishiga, M., Usami, S., Izuhara, M., Sowa, N., Yahagi, N., et al. (2013) · Nature Communications · doi:10.1038/ncomms3883 · Cited by 230
Xu, N., Brodin, P., Wei, T., Meisgen, F., Eidsmo, L., Nagy, N., Kemeny, L., Ståhle, M., Sonkoly, E., & Pivarcsi, A. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.55 · Cited by 231
“, 2008) and miR-21 represses the FGFR2 signaling inhibitor, sprouty 1 (Spry1), in cardiac fibroblasts (Thum et al., 2008).”
BackgroundSmall animal models of heart failure
Riehle, C., & Bauersachs, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz161 · Cited by 229
Self-citationMyocardial AKT: The Omnipresent Nexus
Sussman, M. A., Völkers, M., Fischer, K., Bailey, B., Cottage, C. T., Din, S., Gude, N., Avitabile, D., Alvarez, R., Sundararaman, B., et al. (2011) · Physiological Reviews · doi:10.1152/physrev.00024.2010 · Cited by 229
miRNA Therapeutics: A New Class of Drugs with Potential Therapeutic Applications in the Heart
Bernardo, B. C., Ooi, J. Y., Lin, R. C., & McMullen, J. R. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.107 · Cited by 226
miR-484 regulates mitochondrial network through targeting Fis1
Wang, K., Long, B., Jiao, J.-Q., Wang, J.-X., Liu, J.-P., Li, Q., & Li, P.-F. (2012) · Nature Communications · doi:10.1038/ncomms1770 · Cited by 231
Fang, L., Ellims, A. H., Moore, X.-L., White, D. A., Taylor, A. J., Chin-Dusting, J., & Dart, A. M. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0672-0 · Cited by 227
“ERK pathways [28].”
Dey, N., Das, F., Mariappan, M. M., Mandal, C. C., Ghosh-Choudhury, N., Kasinath, B. S., & Choudhury, G. G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.208066 · Cited by 226
Mir-21 Promotes Cardiac Fibrosis After Myocardial Infarction Via Targeting Smad7
Yuan, J., Chen, H., Ge, D., Xu, Y., Xu, H., Yang, Y., Gu, M., Zhou, Y., Zhu, J., Ge, T., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479995 · Cited by 220
Marquez, R. T., Bandyopadhyay, S., Wendlandt, E. B., Keck, K., Hoffer, B. A., Icardi, M. S., Christensen, R. N., Schmidt, W. N., & McCaffrey, A. P. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.126 · Cited by 223
Diagnostic, functional, and therapeutic roles of microRNA in allergic diseases
Lu, T. X., & Rothenberg, M. E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.039 · Cited by 222
Liu, T., Song, D., Dong, J., Zhu, P., Liu, J., Liu, W., Ma, X., Zhao, L., & Ling, S. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00238 · Cited by 224
“For example, the miR-21 antagonist reduces interstitial fibrosis and attenuates cardiac dysfunction induced by pressure overload in mice (Thum et al., 2008).”
BackgroundmiR-21 and miR-146a: The microRNAs of inflammaging and age-related diseases
Olivieri, F., Prattichizzo, F., Giuliani, A., Matacchione, G., Rippo, M. R., Sabbatinelli, J., & Bonafè, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101374 · Cited by 219
MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice
Horie, T., Baba, O., Kuwabara, Y., Chujo, Y., Watanabe, S., Kinoshita, M., Horiguchi, M., Nakamura, T., Chonabayashi, K., Hishizawa, M., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003376 · Cited by 220
Schelbert, E. B., Fridman, Y., Wong, T. C., Abu Daya, H., Piehler, K. M., Kadakkal, A., Miller, C. A., Ugander, M., Maanja, M., Kellman, P., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2511 · Cited by 219
“End systolic volume index, median (IQR), mL/m2 29 (22-35) 29 (22-35) 28 (21-36) .”
Bioinformatic tools for microRNA dissection
Akhtar, M. M., Micolucci, L., Islam, M. S., Olivieri, F., & Procopio, A. D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1221 · Cited by 215
“It is well established that miRNA deregulation is associated with several human diseases (147–149) including various cancers (150).”
Corsten, M. F., Papageorgiou, A., Verhesen, W., Carai, P., Lindow, M., Obad, S., Summer, G., Coort, S. L. M., Hazebroek, M., van Leeuwen, R., et al. (2012) · Circulation Research · doi:10.1161/circresaha.112.267443 · Cited by 216
Song, Y., Zhang, C., Zhang, J., Jiao, Z., Dong, N., Wang, G., Wang, Z., & Wang, L. (2019) · Theranostics · doi:10.7150/thno.29945 · Cited by 215
“It has been reported that miR21 enhances cardiac fibroblast survival by inhibiting the expression of its target transcript SPRY1, which leads to ERK-MAP kinase activation, cardiac fibrosis and dysfunction [31].”
BackgroundPirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial
Lewis, G. A., Dodd, S., Clayton, D., Bedson, E., Eccleson, H., Schelbert, E. B., Naish, J. H., Jimenez, B. D., Williams, S. G., Cunnington, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01452-0 · Cited by 209
Schlesinger, J., Schueler, M., Grunert, M., Fischer, J. J., Zhang, Q., Krueger, T., Lange, M., Tönjes, M., Dunkel, I., & Sperling, S. R. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001313 · Cited by 213
“The shown transcription network is based on an extensive literature search [7,26,41,43,79–120] and integration of our findings.”
Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis
Ma, X., Kumar, M., Choudhury, S. N., Becker Buscaglia, L. E., Barker, J. R., Kanakamedala, K., Liu, M.-F., & Li, Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103735108 · Cited by 214
“Specifically, up-regulation of Spry1, Pten, and Pdcd4when miR-21 was ablated coincided with reduced phosphorylation of ERK, AKT, and JNK, three major downstream effectors of Ras activation that plays a predominant role in DMBA-initiated skin carcinogenesis.”
BackgroundInfluentialTherapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice
Kölling, M., Kaucsar, T., Schauerte, C., Hübner, A., Dettling, A., Park, J.-K., Busch, M., Wulff, X., Meier, M., Scherf, K., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.08.001 · Cited by 212
“For instance, our group was able to demonstrate that miR-21 silencing in a mouse model of cardiac fibrosis resulted in a dramatic reduction of fibrosis.(13,27) Moreover, Duffield and co-workers underlined the efficacy of miR-21 silencing regarding fibrosis development in mice subjected to unilateral ureteral obstructi…”
BackgroundSelf-citationPreclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease
Huang, C.-K., Kafert-Kasting, S., & Thum, T. (2020) · Circulation Research · doi:10.1161/circresaha.119.315856 · Cited by 210
Self-citationDhingra, R., & Vasan, R. S. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.07.005 · Cited by 203
“[116] Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al.”
BackgroundPreclinical development of a miR-132 inhibitor for heart failure treatment
Foinquinos, A., Batkai, S., Genschel, C., Viereck, J., Rump, S., Gyöngyösi, M., Traxler, D., Riesenhuber, M., Spannbauer, A., Lukovic, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14349-2 · Cited by 212
Self-citationYamanaka, Y., Tagawa, H., Takahashi, N., Watanabe, A., Guo, Y.-M., Iwamoto, K., Yamashita, J., Saitoh, H., Kameoka, Y., Shimizu, N., et al. (2009) · Blood · doi:10.1182/blood-2009-06-222794 · Cited by 209
Li, H., Fan, J., Zhao, Y., Zhang, X., Dai, B., Zhan, J., Yin, Z., Nie, X., Fu, X.-D., Chen, C., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.314898 · Cited by 208
The role of microRNA in modulating myocardial ischemia-reperfusion injury
Ye, Y., Perez-Polo, J. R., Qian, J., & Birnbaum, Y. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00130.2010 · Cited by 209
State of the Art: Clinical Applications of Cardiac T1 Mapping
Schelbert, E. B., & Messroghli, D. R. (2016) · Radiology · doi:10.1148/radiol.2016141802 · Cited by 206
XIONG, B., CHENG, Y., MA, L., & ZHANG, C. (2013) · International Journal of Oncology · doi:10.3892/ijo.2012.1707 · Cited by 204
Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice
Wang, J., Song, Y., Zhang, Y., Xiao, H., Sun, Q., Hou, N., Guo, S., Wang, Y., Fan, K., Zhan, D., et al. (2012) · Cell Research · doi:10.1038/cr.2011.132 · Cited by 202
Urinary miR-210 as a Mediator of Acute T-Cell Mediated Rejection in Renal Allograft Recipients
Lorenzen, J. M., Volkmann, I., Fiedler, J., Schmidt, M., Scheffner, I., Haller, H., Gwinner, W., & Thum, T. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03679.x · Cited by 200
“Interfering with miRNAs in other organ systems has already been shown to alter pathophysiological processes (3,19,20).”
BackgroundSelf-citationCastoldi, G., di Gioia, C. R. T., Bombardi, C., Catalucci, D., Corradi, B., Gualazzi, M. G., Leopizzi, M., Mancini, M., Zerbini, G., Condorelli, G., et al. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22939 · Cited by 202
“…fibrosis is a complex process characterized by dynamic regulation of gene expression/protein translation (Creemers and Pinto, 2011); recently, a link between fibrosis and microRNAs (miRNAs) was established (Thum et al., 2008; Duisters et al., 2009; Bauersachs, 2010; Da Costa-Martins et al., 2010).”
BackgroundYe, Y., Hu, Z., Lin, Y., Zhang, C., & Perez-Polo, J. R. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq053 · Cited by 200
Kawashima, H., Numakawa, T., Kumamaru, E., Adachi, N., Mizuno, H., Ninomiya, M., Kunugi, H., & Hashido, K. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2009.11.057 · Cited by 172
Abels, E. R., Maas, S. L. N., Nieland, L., Wei, Z., Cheah, P. S., Tai, E., Kolsteeg, C.-J., Dusoswa, S. A., Ting, D. T., Hickman, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.036 · Cited by 199
miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in Mice
Clapé, C., Fritz, V., Henriquet, C., Apparailly, F., Fernandez, P. L., Iborra, F., Avancès, C., Villalba, M., Culine, S., & Fajas, L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007542 · Cited by 198
“indicates that miRNAs control basic cell functions, ranging from proliferation to apoptosis [5,6,7].”
BackgroundMicroRNAs as mediators and therapeutic targets in chronic kidney disease
Lorenzen, J. M., Haller, H., & Thum, T. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.26 · Cited by 199
“A variety of studies showed a disease-specific role for selected miRNAs (for example, miR-21 and miR-29 in cardiac fibrosis)”
BackgroundSelf-citationPivotal Role of TGF-β/Smad Signaling in Cardiac Fibrosis: Non-coding RNAs as Effectual Players
Saadat, S., Noureddini, M., Mahjoubin-Tehran, M., Nazemi, S., Shojaie, L., Aschner, M., Maleki, B., Abbasi-kolli, M., Rajabi Moghadam, H., Alani, B., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.588347 · Cited by 179
Of mice and men: models and mechanisms of diabetic cardiomyopathy
Riehle, C., & Bauersachs, J. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-018-0711-0 · Cited by 196
Self-citationIn Vivo Activation of a Conserved MicroRNA Program Induces Mammalian Heart Regeneration
Aguirre, A., Montserrat, N., Zacchigna, S., Nivet, E., Hishida, T., Krause, M. N., Kurian, L., Ocampo, A., Vazquez-Ferrer, E., Rodriguez-Esteban, C., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.10.003 · Cited by 197
Regulation of zebrafish heart regeneration by miR-133
Yin, V. P., Lepilina, A., Smith, A., & Poss, K. D. (2012) · Developmental Biology · doi:10.1016/j.ydbio.2012.02.018 · Cited by 195
MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory Pathways
Davis-Dusenbery, B. N., & Hata, A. (2010) · Genes & Cancer · doi:10.1177/1947601910396213 · Cited by 192
Metadata
- Authors
- Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M. A., Licht, J. D., Pena, J. T. R., Rouhanifard, S. H., Muckenthaler, M. U., Tuschl, T., Martin, G. R., Bauersachs, J., & Engelhardt, S.
- Affiliations
- University of Würzburg (DE)
- Deutsche Forschungsgemeinschaft (DE)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Regulus Therapeutics (United States) (US)
- Alnylam Pharmaceuticals (United States) (US)
- King's College London (GB)
- Northwestern University (US)
- Rockefeller University (US)
- Technical University of Munich (DE)
- Corresponding author
- Bauersachs, Johann
- Engelhardt, Stefan
- ORCID
- Thum, Thomas
- Gross, Carina
- Fiedler, Jan
- Fischer, Thomas
- Kissler, Stephan
- Galuppo, Paolo
- Just, Steffen
- Rottbauer, Wolfgang
- Frantz, Stefan
- Castoldi, Mirco
- Rosenwald, Andreas
- Basson, M. Albert
- Licht, Jonathan D.
- Pena, John T. R.
- Rouhanifard, Sara H.
- Muckenthaler, Martina U.
- Tuschl, Thomas
- Bauersachs, Johann
- Engelhardt, Stefan
- Venue
- Nature
- Published
- 2008-11-30
- Volume
- 456
- Issue
- 7224
- Pages
- 980-984
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2132093971
- Cited by
- 2,349
- References
- 30
- Citations by year
- 2026: 62 · 2025: 70 · 2024: 71 · 2023: 76 · 2022: 106 · 2021: 131 · 2020: 151 · 2019: 138 · 2018: 153 · 2017: 167 · 2016: 150 · 2015: 200 · 2014: 183 · 2013: 203 · 2012: 176
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Cancer Institute (R01CA078711, R01 CA 78711, R01CA059998)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- miR-21, cardiac fibroblasts, heart failure, SPRY1, interstitial fibrosis, cardiac hypertrophy, microRNA silencing, antagomir, fibroblast survival, therapeutic target, cardiomyocytes
- MeSH terms
- Animals, Cell Line, Cell Survival, Cells, Cultured, Disease Models, Animal, Fibroblasts, Humans, Male, Mice, Transgenic, Cardiomyopathies, Gene Silencing, MAP Kinase Signaling System, Myocytes, Cardiac, MicroRNAs, Extracellular Signal-Regulated MAP Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.